Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
David A. Margolis(Triangle), Juan González‐García(Hospital Universitario La Paz), Hans-Jürgen Stellbrink(Infektionsmedizinisches Centrum Hamburg), Joseph J. Eron(University of North Carolina at Chapel Hill), Yazdan Yazdanpanah(Hôpital Bichat-Claude-Bernard), Daniel Podzamczer(Bellvitge University Hospital), Thomas A. Lutz, Jonathan B. Angel(Ottawa Hospital), Gary Richmond(Broward Health), Bonaventura Clotet(Hospital Universitari Germans Trias i Pujol), Félix Gutiérrez(Universitat de Miguel Hernández d'Elx), Louis Sloan(Infectious Disease Consultants), Marty St. Clair(Triangle), Miranda Murray(ViiV Healthcare (United Kingdom)), Susan L. Ford(GlaxoSmithKline (United States)), Joseph Mrus(Triangle), Parul Patel(Triangle), Herta Crauwels(Janssen (Belgium)), Sandy Griffith(Triangle), Kenneth Sutton(Triangle), David Dorey(GlaxoSmithKline (Canada)), Kimberly Y. Smith(Triangle), Peter Williams(Janssen (Belgium)), William Spreen(Triangle)
Cited by 502
Abstract
Related Papers
No related papers found
Powered by citation graph analysis